Arynta™ (lisdexamfetamine) – New drug approval
June 16, 2025 - The FDA approved Azurity Pharmaceuticals’ Arynta (lisdexamfetamine) oral solution, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder (BED) in adults.
Top